1. Al-Momani, E., Zlatopolskiy, B., Solbach, C., Reske, S. N. and Machulla, H. J., Synthesis of 15-(4-[11c]methylphenyl)pentadecanoic(4-[11c]methylphenyl)pentadecanoic acid (meppa) via stille cross-coupling reaction, J Radioanal Nucl Chem 288 (2011), no. 3, 881-886.
  2. Arnold, D., Fietkau, R., Hegewisch-Becker, S., Hohler, T., Knoefel, W. T., Kubicka, S., Lang, H., Liersch, T., Luster, M., Oettle, H., Reinacher-Schick, A., Ridwelski, K., Riess, H., Rodel, C., Ruschoff, J., Schmiegel, W., Schmoll, H. J. and Vanhoefer, U., Gastrointestinal tumors--interdisciplinary discussion over new data, Onkologie 34 Suppl 3 (2011), 1-31.
  3. Dietlein, M., Verburg, F. A., Luster, M., Reiners, C., Pitoia, F. and Schicha, H., One should not just read what one believes: The nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer, Eur J Nucl Med Mol Imaging 38 (2011), no. 5, 793-798.
  4. Giammarile, F., Bodei, L., Chiesa, C., Flux, G., Forrer, F., Kraeber-Bodere, F., Brans, B., Lambert, B., Konijnenberg, M., Borson-Chazot, F., Tennvall, J. and Luster, M., Eanm procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds, Eur J Nucl MEd Mol Imaging 38 (2011), no. 7, 1393-1406.
  5. Glatting, G. and Lassmann, M., Nuclear medicine dosimetry: Quantitative imaging and dose calculations, Z. Med. Phys 21 (2011), no. 4, 246-247.
  6. Hanscheid, H., Reiners, C., Goulko, G., Luster, M., Schneider-Ludorff, M., Buck, A. K. and Lassmann, M., Facing the nuclear threat: Thyroid blocking revisited, J Clin Endocrinol Metab 96 (2011), no. 11, 3511-3516.
  7. Kletting, P., Kiryakos, H., Reske, S. N. and Glatting, G., Analysing saturable antibody binding based on serum data and pharmacokinetic modelling, Phys. Med. Biol. 56 (2011), no. 1, 73-86.
  8. Kletting, P., Reske, S. N. and Glatting, G., Dependence of the anti-cd66 antibody biodistribution on the dissociation constant: A simulation study, Z Med Phys 21 (2011), no. 4, 301-304.
  9. Kletting, P., Bunjes, D., Luster, M., Reske, S. N. and Glatting, G., Optimal preloading in radioimmunotherapy with anti-cd45 antibody, Med. Phys. 38 (2011), no. 5, 2572-2578.
  10. Kratzsch, J., Petzold, A., Raue, F., Reinhardt, W., Bröcker-Preuss, M., Görges, R., Mann, K., Karges, W., Morgenthaler, N., Luster, M., Reiners, C., Thiery, J., Dralle, H. and Fuhrer, D., Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer, Clin. Chem. 57 (2011), no. 3, 467-474.
  11. Krüger, S., Mottaghy, F. M., Buck, A. K., Maschke, S., Kley, H., Frechen, D., Wibmer, T., Reske, S. N. and Pauls, S., Brain metastasis in lung cancer. Comparison of cerebral mri and 18f-fdg-pet/ct for diagnosis in the initial staging, Nuklearmedizin 50 (2011), no. 3, 101-106.
  12. Kull, T., Kletting, P., Reske, S. N. and Glatting, G., Determination of individual organ masses for (90)y-anti-cd66 radioimmunotherapy: Influence on therapy planning, Z Med Phys 21 (2011), no. 4, 305-309.
  13. Lassmann, M., Hänscheid, H., Verburg, F. A. and Luster, M., The use of dosimetry in the treatment of differentiated thyroid cancer, Q J Nucl Med Mol Imaging 55 (2011), no. 2, 107-115.
  14. Luster, M. and Simon, D., Von der fehlenden übertragbarkeit internationaler leitlinien zur schilddrüsendiagnostik, Nuklearmedizin 50 (2011), no. 5, 157-177.
  15. Malik, N., Zlatopolskiy, B. D., Solbach, C., Voelter, W., Reske, S. N. and Machulla, H. J., Mono- and dimethylbenzyls as new protecting groups for no-carrier-added nucleophilic aromatic radiofluorination, J Radioanal Nucl Chem 288 (2011), no. 2, 563–569.
  16. Malik, N., Machulla, H. J., Solbach, C., Winter, G., Reske, S. N. and Zlatopolskiy, B., Radiosynthesis of a new psma targeting ligand ([18f]fpy-dupa-pep), Appl Radiat Isot 69 (2011), no. 7, 1014-1018.
  17. Morgenroth, A., Urusova, E. A., Dinger, C., Al-Momani, E., Kull, T., Glatting, G., Frauendorf, H., Jahn, O., Mottaghy, F. M., Reske, S. N. and Zlatopolskiy, B. D., New molecular markers for prostate tumor imaging: A study on 2-methylene substituted fatty acids as new amacr inhibitors, Chemistry 17 (2011), no. 36, 10144-10150.
  18. Morgenroth, A., Dinger, C., Zlatopolskiy, B. D., Al-Momani, E., Glatting, G., Mottaghy, F. M. and Reske, S. N., Auger electron emitter against multiple myeloma - targeted endo-radio-therapy with (125)i-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine, Nucl Med Biol 38 (2011), no. 7, 1067-1077.
  19. Musholt, T. J., Clerici, T., Dralle, H., Frilling, A., Goretzki, P. E., Hermann, M. M., Kussmann, J., Lorenz, K., Nies, C., Schabram, J., Schabram, P., Scheuba, C., Simon, D., Steinmuller, T., Trupka, A. W., Wahl, R. A., Zielke, A., Bockisch, A., Karges, W., Luster, M. and Schmid, K. W., German association of endocrine surgeons practice guidelines for the surgical treatment of benign thyroid disease, Langenbecks Arch Surg 396 (2011), no. 5, 639-649.
  20. Picchio, M., Briganti, A., Fanti, S., Heidenreich, A., Krause, B. J., Messa, C., Montorsi, F., Reske, S. N. and Thalmann, G. N., The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer, Eur Urol 59 (2011), no. 1, 51-60.
  21. Reiners, C., Hanscheid, H., Luster, M., Lassmann, M. and Verburg, F. A., Radioiodine for remnant ablation and therapy of metastatic disease, Nat Rev Endocrinol 7 (2011), no. 10, 589-595.
  22. Rivkees, S. A., Mazzaferri, E. L., Verburg, F. A., Reiners, C., Luster, M., Breuer, C. K., Dinauer, C. A. and Udelsman, R., The treatment of differentiated thyroid cancer in children: Emphasis on surgical approach and radioactive iodine therapy, Endocr Rev 32 (2011), no. 6, 798-826.
  23. Satzger, I., Klein, M., Loser, C., Mohrle, M., Reske, S., Kapp, A. and Gutzmer, R., [for the benefit of the patient: The sentinel node excision], Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 9 (2011), no. 11, 922-926.
  24. Schulz, A. S., Glatting, G., Hoenig, M., Schütz, C., Gatz, S. A., Grewendorf, S., Sparber-Sauer, M., Muche, R., Kropshofer, G., Suttorp, M., Bunjes, D., Debatin, K.-M., Reske, S. N. and Friedrich, W. Radioimmunotherapy based conditioning for hematopoietic cell transplantation in children with malignant and non-malignant diseases. Blood 117 (2011), no. 17, 4642-4650. mit freundlicher Unterstützung der Deutschen José Carreras Leukämie-Stiftung e. V.
  25. Verburg, F. A., Lassmann, M., Mader, U., Luster, M., Reiners, C. and Hanscheid, H., The absorbed dose to the blood is a better predictor of ablation success than the administered (131)i activity in thyroid cancer patients, Eur J Nucl Med Mol Imaging 38 (2011), no. 4, 673-680.
  26. Verburg, F. A., Kirchgassner, C., Hebestreit, H., Steigerwald, U., Lentjes, E. G., Ergezinger, K., Grelle, I., Reiners, C. and Luster, M., Reference ranges for analytes of thyroid function in children, Horm Metab Res 43 (2011), no. 6, 422-426.
  27. Verburg, F. A., Luster, M., Lassmann, M. and Reiners, C., (131)i therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies, Nuklearmedizin 50 (2011), no. 3, 93-99; quiz N20.